Anita Figueras has been a lung cancer patient since 2014, when she was diagnosed with stage IV adenocarcinoma. She has an EGFR mutation, and has developed the T790M resistance mutation. Anita is on her third line of treatment. She participated in the Clovis Pharmaceuticals’ phase II trial for CO-1686, and spoke to the FDA’s Oncologic Drug Advisory Committee about her experience on the experimental drug. She was diagnosed with MS 20 years ago, and has long experience with living with a chronic illness. Read more.
